129 related articles for article (PubMed ID: 3472489)
1. Comparison of difloxacin, enoxacin, and cefoperazone for treatment of experimental Enterobacter aerogenes endocarditis.
Boscia JA; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1987 Mar; 31(3):458-60. PubMed ID: 3472489
[TBL] [Abstract][Full Text] [Related]
2. Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.
Boscia JA; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1985 May; 27(5):708-11. PubMed ID: 3860186
[TBL] [Abstract][Full Text] [Related]
3. Comparison of difloxacin, enoxacin, and cefazolin for the treatment of experimental Staphylococcus aureus endocarditis.
Boscia JA; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1988 Feb; 32(2):262-4. PubMed ID: 3163241
[TBL] [Abstract][Full Text] [Related]
4. Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.
Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1983 Sep; 24(3):321-4. PubMed ID: 6685454
[TBL] [Abstract][Full Text] [Related]
5. Cefoperazone treatment of experimental endocarditis.
Snepar RA; Carrizosa J; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1981 May; 19(5):773-6. PubMed ID: 6457556
[TBL] [Abstract][Full Text] [Related]
6. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Gilbert M; Boscia JA; Kobasa WD; Kaye D
Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
Papadakis JA; Samonis G; Maraki S; Boutsikakis J; Petrocheilou V; Saroglou G
Chemotherapy; 2000; 46(2):116-21. PubMed ID: 10671762
[TBL] [Abstract][Full Text] [Related]
8. Mezlocillin and ticarcillin alone and combined with gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis.
Levison ME; Kobasa WD
Antimicrob Agents Chemother; 1984 Jun; 25(6):683-6. PubMed ID: 6742813
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1987 Jan; 31(1):102-3. PubMed ID: 3471177
[TBL] [Abstract][Full Text] [Related]
10. [Experimental Enterobacter cloacae endocarditis treated with gentamicin. Predictive value of the in vitro bactericidal rate].
Potel G; Caillon J; Bugnon D; Lecomte P; Drugeon HB; Baron D
Pathol Biol (Paris); 1988 May; 36(5):536-9. PubMed ID: 3043353
[TBL] [Abstract][Full Text] [Related]
11. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
Heifetz CL; Bien PA; Cohen MA; Dombrowski ME; Griffin TJ; Malta TE; Sesnie JC; Shapiro MA; Wold SA
J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
[TBL] [Abstract][Full Text] [Related]
12. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.
Gorzynski EA; Gutman SI; Allen W
Antimicrob Agents Chemother; 1989 Apr; 33(4):591-2. PubMed ID: 2524998
[TBL] [Abstract][Full Text] [Related]
13. Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses.
Scroggs SLP; Andrade CC; Chinnasamy R; Azar SR; Schirtzinger EE; Garcia EI; Arterburn JB; Hanley KA; Rossi SL
Viruses; 2020 Sep; 12(9):. PubMed ID: 32933138
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Hershberger E; Coyle EA; Kaatz GW; Zervos MJ; Rybak MJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1921-4. PubMed ID: 10858355
[TBL] [Abstract][Full Text] [Related]
15. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Hooper DC; Wolfson JS
Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302
[No Abstract] [Full Text] [Related]
16. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
Foot M; Williams G; Want S; Roe M; Quaghebeur G; Bates S
J Antimicrob Chemother; 1988 Feb; 21 Suppl B():97-103. PubMed ID: 3129393
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
[TBL] [Abstract][Full Text] [Related]
18. Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness.
Scroggs SLP; Gass JT; Chinnasamy R; Widen SG; Azar SR; Rossi SL; Arterburn JB; Vasilakis N; Hanley KA
Virology; 2021 Jan; 552():94-106. PubMed ID: 33120225
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
Klesel N; Limbert M; Seibert G; Winkler I; Schrinner E
Infection; 1986; 14 Suppl 1():S36-9. PubMed ID: 2937738
[TBL] [Abstract][Full Text] [Related]
20. Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis.
Piper KE; Rouse MS; Ronningen KL; Steckelberg JM; Wilson WR; Patel R
Antimicrob Agents Chemother; 2000 Sep; 44(9):2554-6. PubMed ID: 10952616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
